The AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test is crucial for patients undergoing treatment for certain types of cancers.this test helps in monitoring minimal residual disease (MRD) effectively, ensuring optimal treatment decisions. It is essential for patients with specific genetic markers related to cancer.
- Call Anytime: +254 704 150555
- info@biopassiondiagnostics.co.ke
AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test
Genetic Testing
AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test
KSh 20,000.00
Regular price
KSh 17,400.00
Current price
-13%
What Is the AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test?
The AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test is a specialized diagnostic tool designed to assist healthcare providers in monitoring the effectiveness of treatment in patients with certain types of cancers. This test is particularly significant for those diagnosed with Acute Myeloid Leukemia (AML) and aims to detect minimal residual disease (MRD), which is crucial for guiding further treatment decisions.
Who Should Consider This Test?
Patients diagnosed with AML or those who have undergone treatment for this condition should consider the AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test. Key indicators include:
- Recent diagnosis of AML
- Previous treatment for AML
- Symptoms indicating potential relapse
What Does the Test Detect or Measure?
This test quantifies the presence of specific gene rearrangements associated with AML. By measuring the levels of these rearrangements, clinicians can determine how well a patient is responding to treatment and if any cancer cells remain.
Test Preparation
The test requires a sample of 5 mL (minimum 3 mL) of whole blood or bone marrow collected in a Lavender Top (EDTA) tube. The sample must be shipped refrigerated and should not be frozen. A duly filled MRD Requisition form (Form 22) with historical data is mandatory for processing.
What the Results May Show
Results from the test will indicate the level of gene rearrangement present in the blood or bone marrow. A higher level may suggest that residual cancer cells remain, while a lower level may indicate a favorable response to treatment. It is essential to discuss results with your healthcare provider to understand their implications fully.
Benefits or Clinical Value
Undergoing the AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test offers several benefits, including:
- Accurate monitoring of treatment efficacy
- Early detection of potential relapses
- Informed decision-making for future treatment options
Pricing
| Test Name | Current Price | Regular Price |
|---|---|---|
| AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test | KSh 17,400.00 | KSh 20,000.00 |
Book the AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test
Contact Biopassion Diagnostics to confirm sample requirements and schedule this test.
SKU: 63923f49e524 | Category: Genetic Testing